Table 1 |.
Prevalence of phenotypes that influence response to cardiovascular pharmacotherapy
| Phenotype | Prevalence | ||||||
|---|---|---|---|---|---|---|---|
| European | African | East Asian | Latino or Native American | Central or South Asian | Middle Eastern | Oceanian | |
| CYP2C19 | |||||||
| Ultra-rapid metabolizer | 0.05 | 0.04 | 0.00 | 0.02 | 0.03 | 0.04 | 0.00 |
| Rapid metabolizer | 0.27 | 0.21 | 0.03 | 0.19 | 0.19 | 0.26 | 0.02 |
| Normal metabolizer | 0.40 | 0.31 | 0.38 | 0.58 | 0.30 | 0.45 | 0.04 |
| Intermediate metabolizer | 0.26 | 0.34 | 0.46 | 0.20 | 0.41 | 0.24 | 0.37 |
| Poor metabolizer | 0.02 | 0.05 | 0.13 | 0.01 | 0.08 | 0.02 | 0.57 |
| CYP2C9 | |||||||
| Normal metabolizer | 0.63 | 0.74 | 0.84 | 0.79 | 0.60 | 0.61 | 0.91 |
| Intermediate metabolizer | 0.35 | 0.25 | 0.15 | 0.20 | 0.36 | 0.36 | 0.09 |
| Poor metabolizer | 0.03 | 0.01 | 0.01 | 0.01 | 0.04 | 0.03 | 0.00 |
| VKORC1 (−1639G>A or rs9923231) | |||||||
| Warfarin-sensitive (A/A) | 0.19 | 0.03 | 0.84 | 0.46 | NA | NA | NA |
| Intermediate warfarin sensitivity (A/G) | 0.41 | 0.06 | 0.16 | 0.42 | NA | NA | NA |
| Warfarin-resistant (G/G) | 0.40 | 0.91 | 0.00 | 0.12 | NA | NA | NA |
| SLCO1B1 (rs4149056) | |||||||
| Normal function (T/T) | 0.71 | 0.98 | 0.76 | 0.89 | NA | NA | NA |
| Intermediate function (C/T) | 0.27 | 0.02 | 0.22 | 0.10 | NA | NA | NA |
| Low function (C/C) | 0.01 | 0 | 0.02 | 0 | NA | NA | NA |